Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Elara MD vs FMmeds

Elara MD
Graded #466

Lower grade

vs+9.700000000000003
FMmeds
Graded #257

Higher grade

The verdict

FMmeds takes it — 63.2/100 to 53.5/100.

FMmeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FMmeds is a Manhattan Beach-based DTC telehealth platform selling compounded semaglutide and tirzepatide co-formulated with vitamin B12, with no membership fee and a free initial visit billed only on approval.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFMmeds +6
40
46
Dose & formulationFMmeds +18
54
72
Clinical oversightFMmeds +7
63
70
Labs & monitoringFMmeds +1
52
53
FulfillmentFMmeds +31
66
97
Contract termsElara MD +8
55
47
Elara MD · left barFMmeds · right bar

The numbers

MetricElara MDFMmeds
WeighScore53.5/10063.2/100
GradeCC
Scorecard rank#466#257
Semaglutide$249/mo (0.2 mg dose, compounded)$225/mo (all doses, compounded)
Tirzepatide$349/mo (2.0 mg dose, compounded)$265/mo (all doses, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Elara MD

Graded #466 · C

Strengths

  • Dose-banded monthly pricing published on-site ($249–$649/mo across tiers)
  • Both a semaglutide-range and a tirzepatide-range (GLP-1/GIP) option, plus microdosing
  • Medication included in the monthly price with free fast shipping when prescribed
  • Broad reach claimed (over 40 states)

Where it loses points

  • Molecules not named on-site (only 'Personalized GLP-1') — compounded status is inferred
  • No FDA compounded-medication disclaimer published
  • No named compounding pharmacy partner — prescriptions are patient-directed
  • LegitScript certification, medical director, and full state list not disclosed
  • Pricier than several compounded competitors
FMmeds

Graded #257 · C

Strengths

  • All 50 states plus DC covered, stated in the Terms
  • Operating LLC and full Manhattan Beach, CA address disclosed
  • Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
  • Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
  • Flat pricing across all dose strengths — no dose-escalation surcharge

Where it loses points

  • Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
  • Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
  • Clinical network not separately named
  • LegitScript Certified, but the specific ID isn't shown
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard